Skip to main content
Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: Differential responses to immune checkpoint inhibitor dictated by pre-existing differential immune profiles in squamous cell carcinomas caused by same initial oncogenic drivers

Fig. 6

Differential ability of TAb2 and TCh3 tumors to upregulate PD-L1 in response to IFN-γ. A Minimal PD-L1 expression in CD45− population of in vivo tumors. Representative flow plots of non-immune cells (CD45− population) (left) and the percentage of PD-L1+ cells in CD45− population of TAb2 (n = 13) and TCh3 (n = 13) tumors (right). B TAb2 and TCh3 tumors do not express PD-L1 at baseline. Representative histograms (left) and mean fluorescent intensities (MFI) (right) of isotype control (negative control) and anti-PD-L1 staining on in vitro cultured tumor cell lines at baseline. C-D TCh3 tumors exhibited enhanced responsiveness to IFN-γ. Representative histograms (C) and MFI of PD-L1 expression (D) of in vitro cultured TAb2 or TCh3 tumor cell lines either untreated or treated with different doses of IFN-γ. Representative results are shown from two independent experiments. Statistical significance is calculated from duplicates in one experiment with unpaired two-tailed t test. Error bars represent the SEM

Back to article page